Sean Laaman is ranked #1800 on 13Foresight, scored on hit rate, average return versus the market, and number of calls.

Sean Laaman

Q: How accurate are Sean Laaman's stock ratings?

About 57% of Sean's ratings were profitable over a one-year hold, with an average return of +2.4% per rating, measured by 13Foresight from historical prices.

Morgan Stanley

Wall Street Analyst

★★★☆☆

#1800

on 13Foresight · ranked by our own returns

57%

Success Rate

+2.3%

Average Return

60 of 106 calls profitable · +23.3% vs benchmark

Time Frame ⓘ

1 Yr 2 Yr 3 Yr 5 Yr

Compared To ⓘ

S&P 500 (SPY)

📈 Across the calls we could measure, roughly 57% of Sean Laaman's ratings turned a profit when each position was held for 1 year — averaging +2.3% per rating. These figures are computed by 13Foresight from historical prices, not supplied by the analyst.

Rating Distribution

108 Buy 62 Hold 4 Sell

Sean's Stock Coverage 41 ratings · 2026-09-26

Company	Date	Position	Consensus ⓘ	Price Target ⓘ	1-Yr Return	vs S&P 500 ⓘ
AXSM Axsome Therapeutics	Sep 25, 2026	HOLD	Strong Buy +21.1% avg upside 30 analysts	$251.00 28.72% Upside	+0.0%	·
BMRN BioMarin Pharmaceutical	Sep 16, 2026	BUY	Strong Buy +58.6% avg upside 52 analysts	$124.00 105.77% Upside	-5.2%	·
CGEM Cullinan Management	Sep 15, 2026	BUY	Strong Buy +136.6% avg upside 16 analysts	$30.00 102.51% Upside	-27.9%	·
NBIX Neurocrine	Sep 11, 2026	HOLD	Strong Buy +35.2% avg upside 37 analysts	$183.00 32.30% Upside	-6.4%	·
RVMD Revolution Medicines	Sep 10, 2026	BUY	Strong Buy -1.5% avg upside 33 analysts	$255.00 24.41% Upside	+0.2%	·
ARGX Argenx Se	Sep 01, 2026	BUY	Strong Buy -13.5% avg upside 48 analysts	$1250.00 30.35% Upside	-6.6%	·
JAZZ Jazz Pharmaceuticals	Aug 26, 2026	BUY	Strong Buy +3.8% avg upside 35 analysts	$322.00 35.40% Upside	-4.5%	·
ACAD ACADIA Pharmaceuticals	Aug 25, 2026	HOLD	Strong Buy +72.2% avg upside 43 analysts	$28.00 35.37% Upside	-32.4%	·
ABSI AbSci	Aug 17, 2026	HOLD	Strong Buy +27.3% avg upside 19 analysts	$10.00 2.66% Upside	+5.2%	·
ERAS Erasca	Aug 17, 2026	HOLD	Strong Buy +46.0% avg upside 14 analysts	$21.00 47.28% Upside	-20.6%	·
RXRX Recursion Pharmaceuticals	Aug 17, 2026	HOLD	Buy +111.1% avg upside 12 analysts	$5.30 41.62% Upside	+19.0%	·
EIKN Eikon Therapeutics, Inc.	Aug 17, 2026	BUY	Buy +210.8% avg upside 5 analysts	$32.00 304.01% Upside	-14.5%	·
ALEC Alector	Aug 17, 2026	SELL	Hold +409.1% avg upside 15 analysts	$2.00 2.57% Upside	+5.9%	·
GENB Generate Biomedicines, Inc.	Aug 17, 2026	BUY	Strong Buy +74.2% avg upside 6 analysts	$22.00 45.12% Upside	-3.4%	·
IRON Disc Medicine	Aug 17, 2026	BUY	Strong Buy +35.5% avg upside 21 analysts	$90.00 38.02% Upside	-18.5%	·
MPLT MapLight Therapeutics, Inc.	Aug 17, 2026	HOLD	Strong Buy +179.4% avg upside 13 analysts	$21.00 100.76% Upside	-7.0%	·
CTNM Contineum Therapeutics, Inc. Class A	Aug 17, 2026	HOLD	Strong Buy +69.2% avg upside 9 analysts	$18.00 43.38% Upside	-6.7%	·
BBOT BridgeBio Oncology Therapeutics	Aug 17, 2026	BUY	Strong Buy +453.4% avg upside 11 analysts	$18.00 355.66% Upside	-56.3%	·
CGON CG Oncology, Inc.	Aug 17, 2026	BUY	Strong Buy +27.3% avg upside 17 analysts	$93.00 38.45% Upside	-10.8%	·
BBIO BridgeBio Pharma	Aug 11, 2026	BUY	Strong Buy +45.3% avg upside 34 analysts	$97.00 47.85% Upside	-22.1%	·
IMCR Immunocore Holdings	Aug 07, 2026	HOLD	Strong Buy +109.5% avg upside 22 analysts	$43.00 39.87% Upside	-9.7%	·
HALO Halozyme	Aug 07, 2026	BUY	Buy -42.9% avg upside 20 analysts	$105.00 7.85% Downside	+9.0%	·
DNLI Denali Therapeutics	Aug 07, 2026	BUY	Strong Buy +90.1% avg upside 24 analysts	$40.00 96.14% Upside	-17.6%	·
ONC BeOne Medicines	Aug 06, 2026	BUY	Strong Buy +0.3% avg upside 28 analysts	$405.00 12.21% Upside	+6.4%	·
EXEL Exelixis	Aug 06, 2026	HOLD	Buy -27.0% avg upside 34 analysts	$53.00 8.92% Downside	+11.8%	·
SDGR Schrodinger	May 14, 2026	HOLD	Strong Buy -7.3% avg upside 16 analysts	$17.00 41.12% Downside	+41.1%	·
AU:SIG Sigma Healthcare Ltd	Aug 28, 2025	BUY	Strong Buy +143.1% avg upside 10 analysts	$3.30 28.44% Upside	-13.1%	·
CERT Certara	Jul 02, 2025	HOLD	Buy +45.3% avg upside 22 analysts	$16.00 75.56% Upside	-39.3%	·
AU:MPL Medibank Private	Feb 12, 2025	HOLD	Hold -3.6% avg upside 2 analysts	$3.95 12.90% Downside	+17.9%	·
RMD Resmed	Aug 01, 2024	HOLD	Buy +4.0% avg upside 27 analysts	—	+31.3%	·
AU:RMD Resmed Inc CHESS Depositary Interests on a ratio of 10 CDIs per ord.sh	Jun 24, 2024	BUY	Strong Buy +27.8% avg upside 11 analysts	$33.70 6.72% Upside	+41.5%	·
AU:CSL CSL	Jun 12, 2024	BUY	Strong Buy +22.1% avg upside 16 analysts	$310.00 75.25% Upside	-15.8%	·
AU:SHL Sonic Healthcare Limited	May 22, 2024	BUY	Buy +34.3% avg upside 12 analysts	$31.65 68.41% Upside	+7.1%	·
AU:ANN Ansell	Apr 09, 2024	HOLD	Hold -20.3% avg upside 9 analysts	$24.14 45.49% Downside	+16.3%	·
AU:COH Cochlear	Mar 21, 2024	SELL	Buy +32.6% avg upside 15 analysts	$256.00 79.85% Upside	+16.9%	·
AU:HLS Healius Limited	Feb 28, 2024	SELL	Sell +123.6% avg upside 10 analysts	$1.30 242.15% Upside	-15.8%	·
AU:NHF NIB Holdings Ltd	Feb 27, 2024	HOLD	Strong Sell +4.0% avg upside 2 analysts	$7.35 14.11% Upside	-5.6%	·
AU:MVF Monash IVF Group Ltd	Feb 26, 2024	BUY	Buy +31.9% avg upside 7 analysts	$1.65 123.06% Upside	-12.5%	·
AU:RHC Ramsay Health Care	Nov 28, 2023	HOLD	Buy -13.8% avg upside 14 analysts	$51.60 6.74% Downside	-17.8%	·
AU:IDX Integral Diagnostics Ltd.	Aug 28, 2023	SELL	Strong Buy +39.8% avg upside 12 analysts	$2.75 24.47% Upside	+7.6%	·
SKHHY Sonic Healthcare	Aug 24, 2021	BUY	Buy 5 analysts	—	-18.6%	·

🔒 36 more ratings — with price targets, crowd consensus and our measured returns.

Free account unlocks every analyst's full coverage table.

Sean Laaman — Frequently Asked Questions

How accurate are Sean Laaman's stock ratings?

Based on the calls 13Foresight could measure, about 57% of Sean's ratings were profitable over a one-year hold, with an average return of +2.4% per rating, or +23.3% versus the S&P 500. We score every analyst the same way, from historical prices. Each return is measured in the stock's own trading currency, so for non-US listings the S&P 500 comparison leaves out currency moves.

How is Sean ranked on 13Foresight?

Sean Laaman is currently ranked #1800 with a 3-star rating. Our rank blends hit rate, average return versus the market, and how many calls we have to judge — so a long, consistent record outweighs a few lucky picks. It is our own calculation, updated daily.

Which stocks does Sean cover?

Sean most recently has ratings on AXSM, BMRN, CGEM, NBIX, RVMD, ARGX, JAZZ, ACAD, ABSI, ERAS, RXRX, EIKN and 29 more. See the full coverage table above for positions, price targets and our measured returns.

Where can I see other analyst ratings?

Browse the full analyst leaderboard to compare Wall Street analysts ranked by their measured performance, success rate and average return.

Disclaimer: 13Foresight compiles analyst ratings and price targets from publicly available sources. Performance metrics, rankings and star ratings shown here are calculated independently by 13Foresight from historical market prices and may differ from figures published elsewhere. This information may be incomplete, delayed or inaccurate, is provided for research and informational purposes only, and is not investment advice. The underlying ratings and opinions are those of the respective analysts and their firms; 13Foresight accepts no liability for any decisions made based on this data.

Sean Laaman

Rating Distribution

Welcome to 13Foresight!